In the present study, we compared the prevalence of actionable genomic vulnerabilities between early- and advanced-stage NSCLC—with a more detailed focus on the EGFR mutational landscape—in a series of 1961 consecutive LUAD patients referred to the Regina Elena National Cancer Institute between 2016 and 2019. Here, EGFR is linked to non-small cell lung carcinoma.